TDR Targets

Basic information

Technical information

TDR Targets ID: 33020
Name: 3-[(3,5-difluorophenyl)methyl]-1H-imidazole-2 -thione
MW: 226.246 | Formula: C10H8F2N2S
H donors: 1 H acceptors: 0 LogP: 1.62 Rotable bonds: 2
Rule of 5 violations (Lipinski): 1
SMILES: Fc1cc(cc(c1)F)Cn1cc[nH]c1=S
InChi: 1S/C10H8F2N2S/c11-8-3-7(4-9(12)5-8)6-14-2-1-13-10(14)15/h1-5H,6H2,(H,13,15)
InChiKey: WPMVQUHUCQAOBU-UHFFFAOYSA-N

Network

Hover on a compound node to display the structore

Target Layer

Model Organisms

Species	Viewmode
Arabidopsis thaliana
Caenorhabditis elegans
Dictyostelium discoideum
Drosophila melanogaster
Escherichia coli
Homo sapiens
Mus musculus
Oryza sativa
Saccharomyces cerevisiae
Schmidtea mediterranea
Other organisms

TDR Pathogens:

Species	Viewmode
Brugia malayi
Chlamydia trachomatis
Echinococcus granulosus
Entamoeba histolytica
Echinococcus multilocularis
Giardia lamblia
Leishmania major
Loa Loa (eye worm)
Mycobacterium leprae
Mycobacterium tuberculosis
Mycobacterium ulcerans
Onchocerca volvulus
Plasmodium falciparum
Plasmodium vivax
Schistosoma mansoni
Trypanosoma brucei
Trypanosoma cruzi
Toxoplasma gondii
Treponema pallidum
Trichomonas vaginalis
Wolbachia endosymbiont of Brugia malayi

Other Pathogens:

Species	Viewmode
Babesia bovis
Candida albicans
Cryptosporidium hominis
Cryptosporidium parvum
Leishmania braziliensis
Leishmania donovani
Leishmania infantum
Leishmania mexicana
Neospora caninum
Plasmodium berghei
Plasmodium knowlesi
Plasmodium yoelii
Schistosoma japonicum
Trypanosoma brucei gambiense
Trypanosoma congolense
Theileria parva

Compound Layer

This is a work in progress. Come back soon to try this features!

Clustering layers

This is a work in progress. Come back soon to try this features!

Synonyms

1-(3,5-difluorobenzyl)-4-imidazoline-2-thione
1-[(3,5-difluorophenyl)methyl]-3H-imidazole-2-thione
1-(3,5-difluorobenzyl)-3H-imidazole-2-thione

Targets

Known targets for this compound

Species	Target name	Source	Bibliographic reference
Homo sapiens	dopamine beta-hydroxylase (dopamine beta-monooxygenase)	Starlite/ChEMBL	References
Bos taurus	Dopamine beta-hydroxylase	Starlite/ChEMBL	References
Rattus norvegicus	Dopamine beta-hydroxylase	Starlite/ChEMBL	References

Predicted pathogen targets for this compound

By orthology

Species	Potential target	Known druggable target/s	Ortholog Group
Schistosoma mansoni	dopamine-beta-monooxygenase	Get druggable targets OG5_129281	All targets in OG5_129281
Schistosoma japonicum	ko:K00503 dopamine beta-monooxygenase [EC1.14.17.1], putative	Get druggable targets OG5_129281	All targets in OG5_129281

By sequence similarity to non orthologous known druggable targets

No druggable targets predicted by sequence similarity

Ranking Plot

Putative Targets List

Species	Potential target	Raw	Global	Species
Echinococcus granulosus	transient receptor potential cation channel	0.0045	0.0003	0.0006
Mycobacterium ulcerans	inosine 5'-monophosphate dehydrogenase	0.0081	0.0455	1
Echinococcus multilocularis	transient receptor potential cation channel	0.0044	0.00000026298	0.0000005237
Leishmania major	inosine-5-monophosphate dehydrogenase	0.0081	0.0455	1
Brugia malayi	Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein	0.0221	0.2194	0.4368
Trypanosoma cruzi	inosine-5'-monophosphate dehydrogenase, putative	0.0081	0.0455	1
Echinococcus multilocularis	transient receptor potential cation channel	0.0045	0.0003	0.0006
Schistosoma mansoni	transient receptor potential channel	0.0044	0.00000026298	0.00000026298
Loa Loa (eye worm)	DOMON domain-containing protein	0.0086	0.0516	0.1027
Trypanosoma cruzi	inosine-5'-monophosphate dehydrogenase, putative	0.0081	0.0455	1
Loa Loa (eye worm)	hypothetical protein	0.0448	0.5021	1
Trichomonas vaginalis	voltage and ligand gated potassium channel, putative	0.0044	0	0.5
Loa Loa (eye worm)	DOMON domain-containing protein	0.0086	0.0516	0.1027
Trypanosoma brucei	inosine-5'-monophosphate dehydrogenase	0.0081	0.0455	1
Trichomonas vaginalis	voltage and ligand gated potassium channel, putative	0.0044	0	0.5
Brugia malayi	DOMON domain containing protein	0.0086	0.0516	0.1027
Trypanosoma cruzi	GMP reductase	0.0081	0.0455	1
Onchocerca volvulus		0.0086	0.0516	1
Mycobacterium tuberculosis	Probable inosine-5'-monophosphate dehydrogenase GuaB2 (imp dehydrogenase) (inosinic acid dehydrogenase) (inosinate dehydrogenase	0.0081	0.0455	0.5
Echinococcus granulosus	transient receptor potential cation channel	0.0044	0.00000026298	0.0000005237
Trypanosoma cruzi	inosine-5'-monophosphate dehydrogenase, putative	0.0081	0.0455	1
Loa Loa (eye worm)	hypothetical protein	0.0044	0.00000026298	0.0000005237
Echinococcus multilocularis	peptidyl glycine alpha amidating monooxygenase	0.0448	0.5021	1
Brugia malayi	Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein	0.0448	0.5021	1
Echinococcus granulosus	transient receptor potential cation channel	0.0044	0.00000026298	0.0000005237
Loa Loa (eye worm)	hypothetical protein	0.0448	0.5021	1
Schistosoma mansoni	peptidylglycine monooxygenase	0.0448	0.5021	0.5021
Brugia malayi	DOMON domain containing protein	0.0086	0.0516	0.1027
Schistosoma mansoni	transient receptor potential channel	0.0044	0.00000026298	0.00000026298
Brugia malayi	DOMON domain containing protein	0.0086	0.0516	0.1027
Brugia malayi	Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein	0.0227	0.2277	0.4534
Leishmania major	guanosine monophosphate reductase	0.0081	0.0455	1
Echinococcus multilocularis	short transient receptor potential channel 6	0.0045	0.0003	0.0006
Onchocerca volvulus		0.0086	0.0516	1
Brugia malayi	Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein	0.0448	0.5021	1
Echinococcus granulosus	short transient receptor potential channel 6	0.0045	0.0003	0.0006
Wolbachia endosymbiont of Brugia malayi	IMP dehydrogenase	0.0081	0.0455	0.5
Schistosoma mansoni	transient receptor potential channel	0.0045	0.0003	0.0003
Schistosoma mansoni	inosine-5-monophosphate dehydrogenase	0.0081	0.0455	0.0455
Toxoplasma gondii	IMP dehydrogenas	0.0081	0.0455	1
Loa Loa (eye worm)	DOMON domain-containing protein	0.0086	0.0516	0.1027
Loa Loa (eye worm)	hypothetical protein	0.0045	0.0003	0.0006
Echinococcus multilocularis	inosine 5' monophosphate dehydrogenase 2	0.0081	0.0455	0.0906
Trypanosoma brucei	GMP reductase	0.0081	0.0455	1
Plasmodium falciparum	inosine-5'-monophosphate dehydrogenase	0.0076	0.0395	0.5
Schistosoma mansoni	peptidyl-glycine monooxygenase	0.0448	0.5021	0.5021
Brugia malayi	olfactory channel protein osm-9	0.0045	0.0003	0.0006
Loa Loa (eye worm)	IMP dehydrogenase 1	0.0081	0.0455	0.0906
Echinococcus granulosus	inosine 5' monophosphate dehydrogenase 2	0.0081	0.0455	0.0906
Trypanosoma cruzi	GMP reductase	0.0081	0.0455	1
Echinococcus multilocularis	transient receptor potential cation channel	0.0045	0.0003	0.0006
Echinococcus granulosus	peptidyl glycine alpha amidating monooxygenase	0.0448	0.5021	1
Plasmodium vivax	inosine-5'-monophosphate dehydrogenase, putative	0.0076	0.0395	0.5
Loa Loa (eye worm)	hypothetical protein	0.0044	0.00000026298	0.0000005237
Mycobacterium leprae	Probable inosine-5'-monophosphate dehydrogenase GuaB2 (IMP dehydrogenase) (IMPDH) (IMPD)	0.0081	0.0455	0.5
Brugia malayi	inosine-5'-monophosphate dehydrogenase family protein	0.0081	0.0455	0.0906

Activities

Activity type	Activity value	Assay description	Source	Reference
-Log IC50 (binding)		Inhibitory activity of the compound towards dopamine beta-hydroxylase (DbetaH) in hypertensive rats when administered orally (or) intraperitoneally activity expressed as log IC50; nd=No data	ChEMBL.	2296023
-Log IC50 (binding)	0	Inhibitory activity of the compound towards dopamine beta-hydroxylase (DbetaH) in hypertensive rats when administered orally (or) intraperitoneally activity expressed as log IC50; nd=No data	ChEMBL.	2296023
-Log IC50 (binding)	= 5.92	Inhibition of dopamine beta hydroxylase	ChEMBL.	7783140
-Log IC50 (binding)	= 5.92	Inhibition of dopamine beta-hydroxylase (DbetaH) in hypertensive rats when administered orally (or) intraperitoneally	ChEMBL.	2296023
Decrease (functional)	= 22 mM	Mean arterial blood pressure at 4 h post drug at po dose of 50 mg/kg for the indicated number of SHR (spontaneous hypertensive rats) relative to blood pressure before dosing (expt. no. 12)	ChEMBL.	3820219
Decrease (functional)	= 28 mM	Mean arterial blood pressure at 4 h post drug at po dose of 50 mg/kg for the indicated number of SHR (spontaneous hypertensive rats) relative to blood pressure before dosing (expt. no. 13)	ChEMBL.	3820219
Decrease (functional)	= 50 mM	Mean arterial blood pressure at 4 h post drug at ip dose of 50 mg/kg for the indicated number of SHR (spontaneous hypertensive rats) relative to blood pressure before dosing	ChEMBL.	3820219
Decrease in blood pressure (functional)	= 50 mmHg	Antihypertensive activity was determined by decrease in blood pressure response in spontaneously hypertensive rat was determined after intraperitoneal administration at a dose of 50 mg/kg	ChEMBL.	3612682
IC50 (binding)	= 5.92	Inhibition of dopamine beta hydroxylase	ChEMBL.	7783140
IC50 (binding)	= 5.92	Inhibition of dopamine beta-hydroxylase (DbetaH) in hypertensive rats when administered orally (or) intraperitoneally	ChEMBL.	2296023
IC50 (binding)	= 5.92	Inhibition of dopamine beta-hydroxylase (DbetaH) enzyme	ChEMBL.	9435905
IC50 (binding)	= 210 nM	Inhibitory activity against bovine adrenal dopamine beta-hydroxylase(DBH)	ChEMBL.	2362264
IC50 (binding)	= 210 nM	Inhibitory activity against bovine adrenal dopamine beta-hydroxylase(DBH)	ChEMBL.	2362264
IC50 (binding)	= 1.2 uM	Inhibition of Dopamine beta hydroxylase in spontaneously hypertensive rats; Value ranges from 1.1-1.4	ChEMBL.	3612682
IC50 (binding)	= 1.2 uM	Inhibitory activity was determined against bovine dopamine beta-hydroxylase(DBH)	ChEMBL.	2299645
IC50 (binding)	= 1.2 uM	Inhibitory Concentration against bovine Dopamine beta hydroxylase (DBH); Range is between (1.0-1.9)	ChEMBL.	3820219
IC50 (binding)	= 1.2 uM	Inhibition of Dopamine beta hydroxylase in spontaneously hypertensive rats; Value ranges from 1.1-1.4	ChEMBL.	3612682
IC50 (binding)	= 1.2 uM	Inhibitory activity was determined against bovine dopamine beta-hydroxylase(DBH)	ChEMBL.	2299645
IC50 (binding)	= 1.2 uM	Inhibitory Concentration against bovine Dopamine beta hydroxylase (DBH); Range is between (1.0-1.9)	ChEMBL.	3820219
Increase (functional)	= 407 %	Percent increase in DA/NE ratio was determined from assay of DA and NE in the mesenteric artery of spontaneously hypertensive rat after two doses of the compound for 50 mg/kg peroral administration	ChEMBL.	3612682
Increase (functional)	= 407 %	Change in DA/NE (Dopamine/Norepinephrine) ratio after oral dosing (50 mg/kg)	ChEMBL.	3820219
Ki (binding)	= 41 nM	Binding affinity towards Dopamine beta hydroxylase using tyramine substrate at pH 4.5 in the absence of fumarate	ChEMBL.	3712378
Ki (binding)	= 41 nM	Binding affinity towards Dopamine beta hydroxylase using tyramine substrate at pH 4.5 in the absence of fumarate	ChEMBL.	3712378
Ki (ADMET)	= 60 nM	DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine	ChEMBL.	2362264
Kis (binding)	ND 0 uM	Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 6.0;ND IS defined as no-data.	ChEMBL.	3820219
Kis (binding)	ND 0 uM	Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH .6.6;ND IS defined as no-data.	ChEMBL.	3820219
Kis (binding)	= 0.041 uM	Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 4.5.	ChEMBL.	3820219
Kis (binding)	= 0.041 uM	Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 4.5.	ChEMBL.	3820219
Level (functional)	= 0.3 ug of tissue	DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 25mg/kg, po	ChEMBL.	3712378
Level (functional)	= 0.765 ug of tissue	DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 25mg/kg,po.	ChEMBL.	3712378
Level (functional)	= 0.809 ug of tissue	DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 50mg/kg, po	ChEMBL.	3712378
Level (functional)	= 1.059 ug of tissue	DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 100mg/kg, po	ChEMBL.	3712378
Level (functional)	= 3.051 ug of tissue	DBH inhibitory activity was measured as NE levels in mesenteric artery at dose of 100mg/kg, po	ChEMBL.	3712378
Level (functional)	= 4.004 ug of tissue	DBH inhibitory activity was measured as NE levels in mesenteric artery at dose of 50mg/kg, po	ChEMBL.	3712378
Level (functional)	= 4.937 ug of tissue	DBH inhibitory activity was measured as NE levels in mesenteric artery at dose of 25mg/kg, po	ChEMBL.	3712378
Level (functional)	= 110 ug of tissue	DBH inhibitory activity was measured as dopamine levels in mesenteric artery at dose of 50mg/kg, po	ChEMBL.	3712378
logP (ADMET)	= 1.98	Partition coefficient (logP)	ChEMBL.	3820219
MAP (functional)	= 105 mmHg	In vivo evaluation ot the compound in spontaneously hypertensive rats for the mean arterial blood pressure	ChEMBL.	3712378
Ratio (functional)	= 0.155	Ratio of dopamine to that of NE levels in mesenteric artery measured at 25 mg/kg po	ChEMBL.	3712378
Ratio (functional)	= 0.204	Ratio of dopamine to that of NE levels in mesenteric artery measured at 50 mg/kg po	ChEMBL.	3712378
Ratio (functional)	= 0.208	In vivo evaluation ot the compound in spontaneously hypertensive rats for the catecholamine levels by taking the ratio of copamine to norepinephrine	ChEMBL.	3712378
Ratio (functional)	= 0.378	Ratio of dopamine to that of NE levels in mesenteric artery measured at 100 mg/kg po	ChEMBL.	3712378

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

ChEMBL: CHEMBL278068
PubChem: 10398787

Bibliographic References

8 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.

Detailed information for compound 33020